Clinical Trials Browser

INDUSTRY × bemarituzumab × Genitourinary × Clear all

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Phase 1 Completed

79 enrolled 21 charts

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03801278 2021-12-13

FPA144

No longer available

Urinary Bladder Neoplasms